HK1133818A1 - Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same - Google Patents
Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the sameInfo
- Publication number
- HK1133818A1 HK1133818A1 HK09110531.6A HK09110531A HK1133818A1 HK 1133818 A1 HK1133818 A1 HK 1133818A1 HK 09110531 A HK09110531 A HK 09110531A HK 1133818 A1 HK1133818 A1 HK 1133818A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- valsartan
- hydrochlorothiazide
- amlodipine
- dosage forms
- solid dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80588306P | 2006-06-27 | 2006-06-27 | |
PCT/US2007/072097 WO2008002905A2 (en) | 2006-06-27 | 2007-06-26 | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1133818A1 true HK1133818A1 (en) | 2010-04-09 |
Family
ID=38662673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09110531.6A HK1133818A1 (en) | 2006-06-27 | 2009-11-11 | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Country Status (23)
Country | Link |
---|---|
US (2) | US20100003321A1 (pt) |
EP (1) | EP2037893A2 (pt) |
JP (1) | JP2009542709A (pt) |
KR (1) | KR20090021191A (pt) |
CN (2) | CN101478956B (pt) |
AR (1) | AR061627A1 (pt) |
AU (1) | AU2007265138A1 (pt) |
BR (1) | BRPI0713785A2 (pt) |
CA (1) | CA2654986A1 (pt) |
CL (1) | CL2007001870A1 (pt) |
EC (1) | ECSP088987A (pt) |
HK (1) | HK1133818A1 (pt) |
IL (1) | IL195797A0 (pt) |
MA (1) | MA30529B1 (pt) |
MX (1) | MX2008016532A (pt) |
NO (1) | NO20090314L (pt) |
NZ (1) | NZ573295A (pt) |
PE (2) | PE20080991A1 (pt) |
RU (1) | RU2449786C2 (pt) |
TN (1) | TNSN08538A1 (pt) |
TW (1) | TW200808379A (pt) |
WO (1) | WO2008002905A2 (pt) |
ZA (1) | ZA200810053B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
KR101813025B1 (ko) | 2009-09-30 | 2017-12-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실치환된 벤질벤젠 유도체의 제조방법 |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
CN101897675B (zh) * | 2010-02-10 | 2012-11-21 | 温士顿医药股份有限公司 | 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物 |
CN101829111B (zh) * | 2010-05-23 | 2014-12-17 | 浙江华海药业股份有限公司 | 含有缬沙坦的固体制剂及其制备方法 |
CN102716132B (zh) * | 2011-03-29 | 2015-09-30 | 石药集团中奇制药技术(石家庄)有限公司 | 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法 |
EP2797580A2 (en) * | 2011-12-26 | 2014-11-05 | Novartis AG | Tablets and dry-coated agents |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN102614190A (zh) * | 2012-04-17 | 2012-08-01 | 北京哈三联科技股份有限公司 | 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法 |
JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
MX358211B (es) | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
CN103655580B (zh) * | 2012-08-28 | 2017-12-01 | 海南中济医药科技有限公司 | 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法 |
WO2014058047A1 (ja) * | 2012-10-12 | 2014-04-17 | 味の素株式会社 | カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法 |
CN102846625A (zh) * | 2012-10-18 | 2013-01-02 | 海口华仕联医药科技有限公司 | 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法 |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2906115T3 (es) | 2013-04-18 | 2022-04-13 | Boehringer Ingelheim Int | Composición farmacéutica, métodos de tratamiento y usos de la misma |
CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
JP6411662B2 (ja) * | 2016-05-30 | 2018-10-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固定容量配合剤 |
CN110325186A (zh) | 2017-02-27 | 2019-10-11 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与活性成分的组合 |
US11382866B2 (en) * | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
WO2022132067A1 (en) * | 2020-12-18 | 2022-06-23 | Santa Farma Ilac Sanayii A.S. | Stable bilayer tablet compositions |
CN113171352A (zh) * | 2021-04-15 | 2021-07-27 | 海南锦瑞制药有限公司 | 一种沙坦类降压复方制剂的制备方法 |
GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
RU2188636C2 (ru) * | 1998-03-26 | 2002-09-10 | Др. Редди'С Лабораторис Лтд. | Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол |
EP1353727A2 (en) | 2000-12-01 | 2003-10-22 | Novartis AG | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
DK1854454T3 (da) * | 2002-01-16 | 2014-01-13 | Boehringer Ingelheim Pharma | Fremgangsmåde til fremstilling af amorf telmisartan |
US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
KR100580168B1 (ko) | 2003-03-21 | 2006-05-16 | 삼성전자주식회사 | 다중 홈 에이전트 제어장치 및 방법 |
US20050209288A1 (en) | 2004-01-12 | 2005-09-22 | Grogan Donna R | Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
CA2564960A1 (en) | 2004-05-21 | 2005-12-01 | Lawrence Solomon | Pharmaceutical tablets having a separation mark positioned on the side of said tablets |
ES2452019T5 (es) * | 2004-11-05 | 2021-06-28 | Boehringer Ingelheim Int | Comprimido bicapa que comprende telmisartán y amlodipino |
CN100389830C (zh) * | 2005-05-08 | 2008-05-28 | 广州市施柏医药科技有限公司 | 一种治疗高血压的药物组合物 |
-
2007
- 2007-06-25 AR ARP070102798A patent/AR061627A1/es not_active Application Discontinuation
- 2007-06-25 PE PE2007000810A patent/PE20080991A1/es not_active Application Discontinuation
- 2007-06-25 PE PE2011001722A patent/PE20120542A1/es not_active Application Discontinuation
- 2007-06-26 WO PCT/US2007/072097 patent/WO2008002905A2/en active Application Filing
- 2007-06-26 NZ NZ573295A patent/NZ573295A/en not_active IP Right Cessation
- 2007-06-26 CL CL200701870A patent/CL2007001870A1/es unknown
- 2007-06-26 BR BRPI0713785-0A patent/BRPI0713785A2/pt not_active IP Right Cessation
- 2007-06-26 RU RU2009102273/15A patent/RU2449786C2/ru not_active IP Right Cessation
- 2007-06-26 CN CN200780024142XA patent/CN101478956B/zh active Active
- 2007-06-26 US US11/915,096 patent/US20100003321A1/en not_active Abandoned
- 2007-06-26 EP EP07799032A patent/EP2037893A2/en not_active Ceased
- 2007-06-26 AU AU2007265138A patent/AU2007265138A1/en not_active Abandoned
- 2007-06-26 MX MX2008016532A patent/MX2008016532A/es not_active Application Discontinuation
- 2007-06-26 CA CA002654986A patent/CA2654986A1/en not_active Abandoned
- 2007-06-26 KR KR1020087031581A patent/KR20090021191A/ko not_active Application Discontinuation
- 2007-06-26 TW TW096123057A patent/TW200808379A/zh unknown
- 2007-06-26 CN CN2013100435988A patent/CN103169711A/zh active Pending
- 2007-06-26 JP JP2009518503A patent/JP2009542709A/ja active Pending
-
2008
- 2008-11-26 ZA ZA200810053A patent/ZA200810053B/xx unknown
- 2008-12-08 IL IL195797A patent/IL195797A0/en unknown
- 2008-12-18 EC EC2008008987A patent/ECSP088987A/es unknown
- 2008-12-24 MA MA31506A patent/MA30529B1/fr unknown
- 2008-12-26 TN TNP2008000538A patent/TNSN08538A1/en unknown
-
2009
- 2009-01-20 NO NO20090314A patent/NO20090314L/no not_active Application Discontinuation
- 2009-11-11 HK HK09110531.6A patent/HK1133818A1/xx not_active IP Right Cessation
-
2012
- 2012-01-03 US US13/342,533 patent/US8475839B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2008016532A (es) | 2009-01-19 |
EP2037893A2 (en) | 2009-03-25 |
CL2007001870A1 (es) | 2008-06-13 |
MA30529B1 (fr) | 2009-06-01 |
JP2009542709A (ja) | 2009-12-03 |
BRPI0713785A2 (pt) | 2012-10-30 |
RU2449786C2 (ru) | 2012-05-10 |
NZ573295A (en) | 2012-01-12 |
CN101478956A (zh) | 2009-07-08 |
AR061627A1 (es) | 2008-09-10 |
IL195797A0 (en) | 2009-09-01 |
RU2009102273A (ru) | 2010-08-10 |
ZA200810053B (en) | 2009-11-25 |
WO2008002905A3 (en) | 2008-12-11 |
KR20090021191A (ko) | 2009-02-27 |
TW200808379A (en) | 2008-02-16 |
TNSN08538A1 (en) | 2010-04-14 |
ECSP088987A (es) | 2009-01-30 |
US8475839B2 (en) | 2013-07-02 |
CA2654986A1 (en) | 2008-01-03 |
PE20120542A1 (es) | 2012-05-14 |
AU2007265138A1 (en) | 2008-01-03 |
US20100003321A1 (en) | 2010-01-07 |
CN103169711A (zh) | 2013-06-26 |
NO20090314L (no) | 2009-01-26 |
US20120164218A1 (en) | 2012-06-28 |
WO2008002905A2 (en) | 2008-01-03 |
PE20080991A1 (es) | 2008-09-05 |
CN101478956B (zh) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1133818A1 (en) | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same | |
TNSN08071A1 (en) | Solid dosage forms of valsartan and amlodipine and method of making the same | |
PL2089922T3 (pl) | Współwytłaczany, wielowarstwowy separator do baterii | |
EP1915227B8 (en) | Composite cutting inserts | |
IL182926A0 (en) | Bilayer tablet comprising telmisartan and amlodipine | |
IL177536A0 (en) | Multilayer tablet | |
PL1885383T3 (pl) | Kocie probiotyczne bifidobakterie | |
ZA200701098B (en) | Bilayer tablet | |
BRPI0718267A2 (pt) | Máquina de formar, encher e selar. | |
GB0423948D0 (en) | Composite materials | |
EP2141361A4 (en) | Hydraulic unit, and construction machine having the unit | |
MY157716A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
EP2025672A4 (en) | 7-ELEMENT HETEROCYCLIC RING, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USES THEREOF | |
WO2007078271A3 (en) | Lansoprazole orally disintegrating tablets | |
WO2007075980A8 (en) | Lansoprazole orally disintegrating tablets | |
GB0405045D0 (en) | Composite materials | |
EP1993161A4 (en) | BATTERY AND BATTERY MANUFACTURING METHOD | |
BRPI0720077A2 (pt) | Formas de dosagem em microemulsão de valsartan e métodos para a produção das mesmas | |
PL2094465T3 (pl) | Sposób wytwarzania wielowarstwowego laminatu i wielowarstwowy laminat | |
FR2903996B1 (fr) | Tablette multicouche a couches de fragmentation. | |
GB0425130D0 (en) | Composite material formation | |
GB2415158B (en) | Die failure detection | |
ZA200403999B (en) | Barrier. | |
HK1073575A2 (en) | Fireproof barrier. | |
AU2005904776A0 (en) | Layered tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170626 |